293.30
+0.68%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About AbbVie
From its filings with the US Securities and Exchange Commission
AbbVie is based in North Chicago, Illinois and is incorporated in Delaware. Its shares trade on NYSE under the ticker ABBV. It is a member of the S&P 500. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $61.16bn and net income of $4.23bn. At that date it held total assets of $133.96bn and shareholders' equity of −$3.27bn. By region, United States accounted for 76.2%, followed by All other countries at 9.4% and Germany at 2.8%.
AbbVie's portfolio of products includes a broad line of therapies that address some of the world's most complex and serious diseases.
In psoriatic disease (plaque psoriasis or psoriatic arthritis), Skyrizi is administered as a quarterly subcutaneous injection following two induction doses. When administered for Crohn’s disease and ulcerative colitis, Skyrizi is given as three induction doses via IV infusion, followed by subcutaneous injection via an on-body injector every eight weeks. Skyrizi is sold in numerous other markets worldwide.
In the United States, Rinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis, active ankylosing spondylitis, active non-radiographic axial spondyloarthritis, moderate to severe ulcerative colitis and moderate to severe active Crohn's disease in adult patients who have an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. For Crohn's disease and ulcerative colitis, it is additionally approved prior to the use of TNF blockers in patients for whom the use of these treatments is clinically inadvisable and who have received at least one approved systemic therapy. It is also indicated for the treatment of adult and pediatric patients two years of age and older with active psoriatic arthritis and for the treatment of patients two years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
Quoted from its 10-K, filed 20 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Jan 2013
- Employees
- 57,000
- Website
- abbvie.com ↗
- Head office
- 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL, 60064
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Robert MichaelChairman of the Board, Chief Executive Officer, since 2017$18.5m
- Mr. Scott ReentsChief Financial Officer, Executive Vice President$11.0m
- Dr. Azita Saleki-GerhardtExecutive Vice President, Chief Operations Officer$9.9m
- Mr. Timothy RichmondChief Human Resources Officer, Executive Vice President$10.3m
- Dr. Roopal ThakkarExecutive Vice President - Research & Development, Chief Scientific Officer
- Mr. Perry SiatisExecutive Vice President, General Counsel, Secretary
- Dr. Nicholas DonoghoeExecutive Vice President, Chief Business and Strategy Officer
- Mr. Jeffrey StewartExecutive Vice President, Chief Commercial Officer$14.0m
- Mr. David PurdueSenior Vice President, Controller
- Ms. Roxanne AustinLead Independent Director$456,668
- Dr. Robert AlpernIndependent Director$525,477
- Mr. William BurnsideIndependent Director$369,818
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 67
- Environment
- 63
- Social
- 94
- Governance
- 44
- Direct emissions (scope 1)
- 300,072 t
- Energy emissions (scope 2)
- 241,142 t
- Women in the workforce
- 56%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Abbvie Inc has several strengths that contribute to its success in the pharmaceutical industry. Firstly, the company possesses a strong portfolio of patented drugs, providing a competitive advantage and ensuring a steady revenue stream. Additionally, Abbvie has a robust research and development (R&D) pipeline, constantly working on innovative therapies and treatments. This allows the company to stay ahead of competitors and meet the evolving needs of patients.
Weaknesses
- Despite its strengths, Abbvie Inc faces certain weaknesses that could hinder its growth. One significant weakness is its heavy dependence on a few key drugs for a significant portion of its revenue. This makes the company vulnerable to patent expirations and the entry of generic competitors. Furthermore, Abbvie has limited international market presence compared to some of its competitors, which reduces its global reach and potential market share.
Opportunities
- There are several opportunities that Abbvie Inc can capitalize on to drive future growth. Expanding into emerging markets such as China and India presents significant potential as these markets are experiencing rapid economic growth and an increasing demand for quality healthcare. Moreover, Abbvie can explore strategic partnerships or acquisitions to diversify its product portfolio and gain access to new markets or technologies. Additionally, the growing focus on personalized medicine opens avenues for the company to develop targeted therapies and further differentiate itself.
Threats
- Abbvie Inc faces certain threats that could impact its performance and market position. One major threat is the increasing competition in the pharmaceutical industry, both from established players and new entrants. This intensifies pricing pressures and requires Abbvie to continuously innovate and differentiate its offerings. Additionally, regulatory and political uncertainties, such as changes in healthcare policies or drug pricing regulations, pose risks to the company's operations and profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.